Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors
MWN-AI** Summary
Apellis Pharmaceuticals, Inc. recently announced the appointment of Mikael Dolsten, M.D., Ph.D., to its board of directors, effective March 1, 2026. Dr. Dolsten is a distinguished figure in the pharmaceutical industry, having served over 16 years as Pfizer’s chief scientific officer and president of worldwide research, development, and medical. His tenure at Pfizer was marked by the successful regulatory approval of more than 36 medicines and vaccines, underscoring his expertise in bringing innovative therapies to market.
Dr. Cedric Francois, CEO and co-founder of Apellis, expressed enthusiasm about Dolsten's addition to the board, noting his extensive experience in pharmaceutical research and development as a key asset for the company's future endeavors, particularly in advancing Apellis' complement pipeline. Before his time at Pfizer, Dolsten held leadership positions at several prominent companies, including Wyeth and AstraZeneca, demonstrating a broad and deep understanding of the biopharmaceutical landscape.
In addition to his role at Apellis, Dolsten serves on the boards of Agilent Technologies and Rocket Pharmaceuticals, and has leadership positions in various private companies, enhancing his strategic influence in the sector. He is also a senior advisor for top financial firms, reflecting his strong business acumen.
Expressing his commitment to Apellis, Dr. Dolsten highlighted the significant potential of complement therapies to address severe medical conditions. He looks forward to leveraging his research and development expertise to support Apellis in its mission. Apellis Pharmaceuticals is recognized for its groundbreaking achievements in complement science, having introduced the first new class of complement medicines in 15 years and currently offering therapies for serious conditions, including geographic atrophy and C3G. This appointment marks a pivotal step as Apellis aims to expand its innovative therapeutic pipeline.
MWN-AI** Analysis
Apellis Pharmaceuticals (Nasdaq: APLS) has recently announced the appointment of Dr. Mikael Dolsten, a veteran biopharmaceutical executive, to its board of directors. This development comes at a crucial time as Apellis progresses its complement therapy pipeline, which has shown significant promise in treating serious and rare diseases. Dr. Dolsten's extensive experience, particularly from his tenure at Pfizer, is expected to bolster Apellis' strategic direction and innovation capabilities.
Investors should note that the addition of Dr. Dolsten reflects Apellis' commitment to strengthening its leadership team with expertise stemming from successful drug development tracks. His role in overseeing regulatory approvals for over 36 medicines could provide invaluable insight into navigating complex clinical pathways and enhancing investor confidence. Furthermore, his connections with various companies and financial advisory groups underline potential partnerships or funding opportunities that could accelerate product development.
The current landscape for complement therapies remains competitive, yet Apellis has established itself as a pioneer, particularly with its recent approvals for C3-targeting medicines. As the first company to introduce such therapies in the current era, it’s positioned uniquely to capture market share. Investors should be optimistic about the long-term potential of Apellis, especially as Dr. Dolsten's vision aligns with the company's mission to unlock new treatments for significant health challenges.
Given the volatility usually associated with biopharmaceutical stocks, potential investors should closely monitor developments within Apellis, including clinical trial results and market reception to its therapies. As more data becomes available, the stock's performance could be influenced positively or negatively, providing opportunities for tactical entry points. In summary, Apellis presents a promising investment opportunity backed by experienced leadership, an innovative pipeline, and strong market positioning in the biopharmaceutical sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that Mikael Dolsten, M.D., Ph.D., has joined the company’s board of directors as of March 1. Most recently, Dr. Dolsten served for more than 16 years as chief scientific officer and president, worldwide research, development and medical, at Pfizer, during which he presided over the regulatory approval of more than 36 medicines and vaccines.
“We are thrilled to welcome Mikael to the Apellis Board of Directors,” said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. “Mikael is a proven industry leader with deep experience developing innovative medicines. His strategic insight and expertise will be a valuable asset as we continue to advance our robust complement pipeline.”
Dr. Dolsten brings extensive pharmaceutical research and development experience to the Apellis Board. Prior to Pfizer, Dr. Dolsten held senior research and leadership positions at Wyeth Pharmaceuticals, Boehringer Ingelheim, AstraZeneca, Pharmacia, and Upjohn.
He currently serves on the boards of directors of public companies Agilent Technologies, Inc., and Rocket Pharmaceuticals. He is chairman or board director of several private companies including Orbis Medicines, Orogen Therapeutics, Quarry Thera, ChAi Discovery, Enveda Bio and Arbor Biotechnologies. Dr. Dolsten is also a senior advisor for financially oriented business groups such as Blackstone, GV (Google Ventures), Bain & Company, Sutter Hill Ventures, Canaan Partners and Formation Bio.
“Apellis has established itself as the leading complement company, and I am excited to join its Board of Directors,” said Dr. Dolsten. “Complement therapies have tremendous potential to help patients across a wide range of serious conditions, and I look forward to bringing my R&D and broad global biopharmaceutical experience to help advance Apellis’ highly innovative pipeline.”
Dr. Dolsten has published approximately 160 scientific articles and book reviews. He earned his M.D. and Ph.D. from Lund University in Sweden, where he also served as an adjunct professor.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first-ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on LinkedIn and X.
Apellis Forward-Looking Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors discussed in the “Risk Factors” section of Apellis’ Annual Report on Form 10-K with the Securities and Exchange Commission on February 28, 2025 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Media:
Tracy Vineis
media@apellis.com
617.420.4839
Investors:?
Eva Stroynowski
ir@apellis.com
617.938.6229
FAQ**
How might Dr. Mikael Dolsten's experience at Pfizer influence the strategic direction of Apellis Pharmaceuticals Inc. (APLS) in advancing its complement pipeline?
Given Dr. Dolsten's extensive background, what specific initiatives can investors expect from Apellis Pharmaceuticals Inc. (APLS) to enhance its position in the biopharmaceutical market?
With the approval of new therapies, how will Apellis Pharmaceuticals Inc. (APLS) leverage Dr. Dolsten's insights to further innovate in complement science?
What are the potential implications for Apellis Pharmaceuticals Inc. (APLS) shareholders following Dr. Dolsten's appointment to the board, especially concerning the development of rare disease treatments?
**MWN-AI FAQ is based on asking OpenAI questions about Apellis Pharmaceuticals Inc. (NASDAQ: APLS).
NASDAQ: APLS
APLS Trading
-1.26% G/L:
$19.62 Last:
352,492 Volume:
$19.89 Open:
